Pierre-andre A. Becherel
Antony, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic Dermatitis.
Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic Dermatitis.
Journal: Dermatology and therapy
Published: May 15, 2026
Dupilumab in moderate-to-severe prurigo nodularis: Real-world data from early access program.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: November 14, 2025
Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativa.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 24, 2025
Clinical Impact of Systemic Treatment Choices Made in Current Practice in Elderly Patients with Atopic Dermatitis.
Journal: Acta dermato-venereologica
Published: July 02, 2025
An update on the medical treatments of hidradenitis suppurativa.
Journal: European journal of dermatology : EJD
Published: June 18, 2025
Real-World Use of Dupilumab in Atopic Dermatitis: Observational Study Results Linked to SNDS.
Journal: Fundamental & clinical pharmacology
Published: March 18, 2025
Vilobelimab to improve clinical outcomes in moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: results of the SHINE double-blind placebo-controlled randomized trial.
Journal: The British journal of dermatology
Published: February 02, 2025
Implementation Science to Improve the Diagnosis and Management of Hidradenitis Suppurativa: HELyx Study Design Overview.
Journal: Dermatology and therapy
Published: November 13, 2024
Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study.
Journal: Acta dermato-venereologica
Published: October 16, 2024
Generalized pustular psoriasis: a multicentric study on patient characteristics and clinical burden.
Generalized pustular psoriasis: a multicentric study on patient characteristics and clinical burden.
Journal: Orphanet journal of rare diseases
Published: May 16, 2024
Janus kinase inhibitors for the treatment of atopic dermatitis: Real-life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee recommended measures.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: April 26, 2023
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Journal: Lancet (London, England)
Published: November 29, 2022
Last Updated: 09/26/2026